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910Objective: To analyze the outcomes of patients with pulmonary arterial hypertension referred for lung trans-
plantation and determine the changes over time.
Methods: All patients with pulmonary arterial hypertension referred for lung transplantation in our program
from January 1997 to September 2010 were reviewed. Pulmonary arterial hypertension was classified as
idiopathic (n ¼ 123) or associated with congenital heart disease (n ¼ 77), connective tissue disease
(n ¼ 102), or chronic thromboembolic disease (n ¼ 14).
Results: After completing their assessment, 61 patients (19%) were found to be unsuitable for lung transplan-
tation, 38 (12%) refused lung transplantation, 65 (21%) were too early to be listed, and 48 (15%) died before
their assessment (n ¼ 34) or being listed (n ¼ 14). Of the 100 patients listed for lung transplantation, 57 under-
went bilateral lung transplantation, 22 underwent heart–lung transplantation, 18 died while waiting, and 3 were
still waiting. The waiting list mortality was the greatest for patients with connective tissue disease–pulmonary
arterial hypertension (34% vs 11% in the remaining patients, P ¼ .005). The number of patients admitted to
the hospital to be bridged to lung transplantation increased from 7% in the 1997–2004 cohort to 25% in the
2005–2010 cohort (P ¼ .02). After lung transplantation, the 30-day mortality decreased from 24% in the
1997–2004 group to 6% in the 2005–2010 group (P ¼ .007). The 10-year survival was worse for those with
idiopathic pulmonary arterial hypertension (42% vs 70% for the remaining patients, P ¼ .01). The
long-term survival reached 69% at 10 years in the patients with connective tissue disease pulmonary arterial
hypertension.
Conclusions: Lung transplantation is an option for about one third of the patients with pulmonary arterial
hypertension referred for lung transplantation. The 30-day mortality after lung transplantation improved signif-
icantly over time, but the long-term survival remained similar between the two cohorts. Patients with connective
tissue disease–pulmonary arterial hypertension have a high mortality on the waiting list but excellent long-term
survival. (J Thorac Cardiovasc Surg 2012;143:910-8)Lung transplantation is the only therapeutic option for
patients with pulmonary arterial hypertension (PAH)
when medical therapy fails. However, lung transplantation
for patients with PAH has generally been hindered by
high mortality on the waiting list and in the early post-
transplant period. A recent analysis of the United Network
for Organ Sharing data demonstrated that the waiting list
mortality for patients with idiopathic PAH (iPAH) was
20% at 1 year after listing, and the mortality after transplan-
tation was 18% at 1 year after surgery.1 The analysis alsoe Toronto Lung Transplant Program and Pulmonary Hypertension Program,
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The Journal of Thoracic and Cardiovascular Surgshowed that, in contrast to other indications for lung trans-
plantation, the 1-year mortality for patients with iPAH is
predominantly driven by the mortality occurring within
the first 30 days after transplantation.1 According to the
registry from the International Society for Heart and Lung
Transplantation, patients with iPAH surviving beyond 30
days after transplantation have long-term outcomes similar
to those of patients undergoing lung transplantation for
indications other than iPAH.2
During the past several years, the perioperative manage-
ment of patients undergoing lung transplantation has
improved substantially, and several experienced centers
have reported an overall 30-day mortality of less than 5%
after lung transplantation.3,4 The implementation of
extracorporeal life support (ECLS) in the pretransplant
setting has also helped to successfully bridge an
increasing number of patients with respiratory failure to
lung transplantation.5 The effect of these improvements
on the pre- and post-transplant outcome of patients with
PAH is unclear.
The population of patients with PAH undergoing lung
transplantation can be divided into three categoriesery c April 2012
Abbreviations and Acronyms
CHD ¼ congenital heart disease
CT ¼ computed tomography
CTD ¼ connective tissue disease
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
ECLS ¼ extracorporeal life support
GERD ¼ gastroesophageal reflux disease
iPAH ¼ idiopathic pulmonary arterial
hypertension
PAH ¼ pulmonary arterial hypertension
PGD ¼ primary graft dysfunction
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sification: iPAH, PAH associated with congenital heart dis-
ease (CHD-PAH), and PAH associated with connective
tissue disease (CTD-PAH). The number of patients with
a diagnosis of iPAH, CHD-PAH, and CTD-PAH represents
less than 5% of all patients undergoing lung transplantation
worldwide; therefore, few studies have compared the out-
comes of patients with PAH before and after lung transplan-
tation.2 In the present study, we reviewed our experience
with all patients with PAH referred to the Toronto Lung
Transplant Program during the past 14 years and compared
the outcomes before and after lung transplantation for
iPAH, CHD-PAH, and CTD-PAH. The changes over time
were analyzed by comparing two cohorts of patients:
1997 to 2004 and 2005 to 2010.
MATERIALS AND METHODS
All patients referred for lung or heart–lung transplantation in our pro-
gram from January 1, 1997 to September 10, 2010 were retrospectively re-
viewed from a prospectively collected database after the University Health
Network Research Ethics Board had approved the study and waived the
need for informed consent. The diagnosis was reviewed for all patients
with PAH. Patients with PAH were then classified into different categories
according to the Dana Point classification.6 Heritable and anorexigen-
mediated PAH were classified with iPAH, because these conditions only
involve the pulmonary vasculature. Patients with associated conditions
were divided into those with CTD-PAH and CHD-PAH. Patients with
PAH related to portal hypertension, chronic hemolytic anemia, human
immunodeficiency virus infection, and schistosomiasis were excluded
from the present study, because these patients are rarely or never referred
for lung transplantation.
Patients with chronic thromboembolic pulmonary hypertension
(CTEPH) who had pulmonary endarterectomy and recurrence of pulmo-
nary hypertension or patients with CTEPH deemed not to be candidates
for pulmonary endarterectomy were included in the present study, because
these patients can have an underlying PAH component to their disease.6We
were also interested in determining the number of patients with CTEPH
referred for lung transplantation since we had started the pulmonary endar-
terectomy program in our institution in 2005. Ventilation/perfusion scans
were used to differentiate PAH from CTEPH. CTEPH was then confirmed
by pulmonary angiography and computed tomography (CT) pulmonary an-
giography. Our indication for pulmonary endarterectomy has evolved overThe Journal of Thoracic and Cathe years, but we currently considered pulmonary endarterectomy for all
patients with evidence of chronic thromboembolic disease localized in
the segmental arteries or more proximally on the pulmonary angiogram
and/or CT pulmonary angiogram, regardless of the degree of right ventric-
ular dysfunction or the severity of the pulmonary vascular resistance.
We recommend that patients with PAH be assessed for transplantation
when intravenous epoprostenol is being considered, with a plan to list
them when they deteriorate clinically to New York Heart Association class
III or IV despite optimal medical therapy, including intravenous epopros-
tenol. We believe that early assessment is crucial for these patients, even
if the time of listing is delayed by several years (through the use of medical
treatment) to ensure that patients understand the implication of the trans-
plant option and to be able to provide rapid listing in the event their clinical
course is more precarious than expected. The use of intravenous epopros-
tenol started in 1997 in our institution. In 2006, we implemented the option
of ECLS to bridge patients with PAH to lung transplantation. The pumpless
Novalung (NovalungGmbH, Hechingen, Germany) connected between the
pulmonary artery and the left atrium was used as the preferred option for
these patients.7
All patients with PAH listed for lung transplantation underwent right
heart catheterization before their referral or before being listed. Pulmonary
hypertension was defined as a mean pulmonary artery pressure greater than
25 mm Hg with a pulmonary capillary wedge pressure of less than 15 mm
Hg. Occasionally, patients with CTD who were deemed too healthy to be
listed had their right heart catheterization delayed until the time of listing.
In these situations, if right heart catheterization had not been done by
September 2010, a calculated pulmonary artery systolic pressure greater
than 40mmHg at rest on the echocardiogramwas used to define pulmonary
hypertension to ensure that the denominator of patients with CTD-PAHwas
as complete as possible. Patientswith severe interstitial lung disease defined
by a total lung capacity less than 60%were excluded from the present study.
The donor and recipient management has been reviewed in detail
elsewhere.8 In brief, all donors received intravenous methylprednisolone
(15 mg/kg, Solu-Medrol, Upjohn, Don Mills, ON, Canada) after brain
death declaration. The donors were maintained euvolemic to avoid excess
fluid administration, and vasopressin and/or noradrenaline were often used
to maintain adequate blood pressure. Low potassium dextran solution (Per-
fadex, Vitrolife, Goteborg, Sweden) has been used for all lung preservation
sinceApril 1998. A retrograde flush has been added to the anterograde flush
since 2001. Severe primary graft dysfunction (PGD) was defined according
to the International Society for Heart and Lung Transplantation definition
as grade III PGD during the initial 72 hours after transplantation.
Since 1994, the policy in our program has been to offer bilateral lung
transplantation to all patients diagnosed with PAH. Heart–lung transplan-
tation was considered only for patients with evidence of severe left ventric-
ular dysfunction (left ventricular ejection fraction <40%) on the
echocardiogram and/or the presence of technical limitations to conduct bi-
lateral lung transplantation. Bilateral lung transplantations were performed
through a clamshell incision and heart–lung transplantations through
a clamshell incision or sternotomy. The approach to bilateral lung trans-
plantation has not changed over time, and all but 1 patient underwent bilat-
eral sequential lung transplantation in the present series. One patient with
CHD underwent en bloc double lung transplantation for anatomic reasons.
Organ allocation in Canada has remained the same during the study
period. All lung donors located in Ontario were allocated to Toronto. Do-
nors from other provinces were allocated to the local program if there was
one. If there was no program, the lungs were sequentially offered to the dif-
ferent lung transplant centers throughout Canada. Transplant physicians
from the selected transplant center then chose the recipient on the basis
of blood group, size match, patient status, and duration on the waiting list.
To define the changes over time, the patients were divided into 2
cohorts, 1997 to 2004 and 2005 to 2010. The cutoff between the 2 cohorts
was at the time of referral, point of listing, and time of transplantation.
Follow-up was complete until September 2010 for all patients.rdiovascular Surgery c Volume 143, Number 4 911
TABLE 1. Outcome of patients referred for lung transplantation assessment
Variable Overall (n) iPAH (n) CHD-PAH (n) CTD-PAH (n) CTEPH (n)
Total patients 316 123 77 102 14
Period
1997–2004 155 64 39 44 8
2005–2010 161 59 38 58 6
Assessment outcome
Unsuitable 61 (19) 20 (16) 20 (26) 18 (18) 3 (21)
Suitable but too early 69 (22) 31 (25) 16 (21) 19 (19) 3 (21)
Death before assessment 34 (11) 13 (11) 8 (10) 12 (12) 1 (7)
Death before listing 14 (4) 5 (4) 2 (3) 6 (6) 1 (7)
Undecided/refused 38 (12) 11 (9) 8 (10) 18 (18) 1 (7)
Listed 100 (32) 43 (35) 23 (30) 29 (28) 5 (36)
Data in parentheses are percentages. iPAH, Idiopathic pulmonary arterial hypertension; CHD, congenital heart disease; CTD, connective tissue disease; CTEPH, chronic throm-
boembolic pulmonary hypertension.
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Student t test or 1-way analysis of variance was used to test for differences
between the continuous variables, and the chi-square test was used for the
categorical variables. Survival was calculated using the Kaplan-Meier
method, and survival curves were compared using the log-rank test. Graph-
Pad (GraphPad Software, San Diego, Calif) was used for all analyses.0
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FIGURE 1. Referrals to the Toronto Lung Transplant Program by year ac-
cording to underlying category of pulmonary arterial hypertension (PAH).
CTEPH, Chronic thromboembolic pulmonary hypertension; CTD, connec-
tive tissue disease; CHD, congenital heart disease; iPAH, idiopathic PAH.RESULTS
Of 2918 patients referred to our program since 1997, 316
(11%) presented with PAH (Table 1). PAHwas classified as
iPAH in 123, CHD-PAH in 77, CTD-PAH in 102, and
CTEPH in 14. CTD was related to scleroderma in 83, lupus
erythematosus in 13, rheumatoid arthritis in 3, Sj€ogren syn-
drome in 2, and polymyositis in 1. The number of referrals
between the first (n ¼ 155) and second (n ¼ 161) cohort of
patients was similar. The number of referrals for patients
with iPAH and CTD-PAH increased over time, and the
number of patients with CTEPH referred for lung transplan-
tation decreased after the implementation of our pulmonary
endarterectomy program (Figure 1).
After completing their assessment, 100 patients (32%)
were listed for transplantation, 69 (22%) were suitable but
too early, 38 (12%) were undecided or refused transplanta-
tion, and 48 (15%) died before being assessed (n ¼ 34) or
listed (n ¼ 14; Table 1). A total of 61 patients (19%) were
found to be unsuitable for transplantation. The proportion
of unsuitable patients decreased over time (23% in the first
cohort vs 15% in the second cohort,P¼ .07), particularly in
patients with CTD-PAH (Table 2). The proportion of
patients dying before being assessed or listed did not change
over time (Table 2).
A total of 79 patients underwent transplantation, 18 died
on thewaiting list, and 3 were still alive on thewaiting list as
of September 2010 (Table 3). The proportion of patients
dying on the waiting list was greater for those with CTD-
PAH than for the other groups of patients with PAH (34%
vs 11%, respectively; P ¼ .006). In the group of patients
diagnosed with iPAH, the mortality on the waiting list
decreased significantly between the first and second cohort912 The Journal of Thoracic and Cardiovascular Surgas a consequence of a greater number of patients admitted to
the hospital and started on ECLS to be bridged to transplan-
tation (Table 2). In contrast, the number of patients with
CTD-PAH and CHD-PAH admitted to hospital to be
bridged to transplantation remained small, and the waiting
list mortality did not change over time for these 2 groups
of patients.
The vast majority of patients with CHD-PAH underwent
heart–lung transplant (81%), and the vast majority of
patients with iPAH and CTD-PAH underwent bilateral
lung transplantation (89% and 94%, respectively). This
resulted in a significantly longer time on the waiting list
for patients with CHD-PAH than for patients with iPAH
and CTD-PAH (Table 3). At transplantation, 2 patients
with CHD-PAH required reconstruction of the superior
vena cava and inferior vena cava for situs inversus
(n ¼ 1) and situs solitus (n ¼ 1), and 1 each underwent
replacement of the ascending aorta and aortic arch. In addi-
tion, 7 patients underwent repair of the tricuspid valve
(n ¼ 3), atrial septal defect closure (n ¼ 2), patent ductus
arteriosus closure (n ¼ 1), and interpositionery c April 2012
TABLE 2. Changes over time
Variable 1997–2004 2005–2010 P value
iPAH
Referrals 64 59
Unsuitable for Tx 11 (17) 9 (15) .8
Died before being assessed or listed 10 (16) 8 (14) .7
Undecided/refused 7 (11) 4 (7) .4
Patients listed 20 23
Admitted to hospital to be bridged to Tx 1 (5) 10 (43) .004
ECLS to be bridged to Tx 0 6 (26) .01
Waiting list mortality 5 (25) 0 .01
Patients transplanted 13 25
30-d Mortality after Tx 3 (23) 2 (8) .2
Length of ICU stay (d) 16  13 32  29 .07
CTD-PAH
Referrals 44 58
Unsuitable for Tx 12 (27) 6 (10) .03
Died before being assessed or listed 12 (27) 6 (10) .3
Undecided/refused 8 (18) 10 (17) .9
Patients listed 6 23
Admitted to hospital to be bridged to Tx 0 3 (13) .4
ECLS to be bridged to Tx 0 1 (4) .4
Waiting list mortality 3 (50) 7 (30) .4
Patients transplanted 3 13
30-d Mortality after Tx 1 (33) 0 .03
Length of ICU stay (d) 10  13 15  10 .5
CHD-PAH
Referrals 38 39
Unsuitable for Tx 11 (29) 9 (23) .6
Died before being assessed or listed 6 (16) 4 (10) .5
Undecided/refused Tx 4 (11) 4 (10) .9
Patients listed 15 8
Admitted to hospital to be bridged to Tx 2 (13) 1 (13) .9
ECLS to be bridged to Tx 0 0 NA
Waiting list mortality 1 (7) 1 (13) .6
Patients transplanted 12 9
30-d Mortality after Tx 3 (25) 1 (11) .6
Length of ICU stay (d) 10  9 9  7 .8
CTEPH
Referrals 8 6
Unsuitable for Tx 2 (8) 1 (14) .6
Died before being assessed or listed 1 (13) 1 (14) .9
Undecided/refused Tx 0 1 (17) NA
Patients listed 3 2
Admitted to hospital to be bridged to Tx 0 0 NA
ECLS to be bridged to Tx 0 0 NA
Waiting list mortality 1 (33) 0 NA
Patients transplanted 1 3
30-d Mortality after Tx 0 0 NA
Length of ICU stay (d) 5 31  4 NA
Data presented as number of patients, with percentages in parentheses or mean  standard deviation. iPAH, Idiopathic pulmonary arterial hypertension; Tx, transplantation;
ECLS, extracorporeal life support; ICU, intensive care unit; CTD, connective tissue disease; CHD, congenital heart disease; NA, not applicable;CTEPH, chronic thromboembolic
pulmonary hypertension.
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main pulmonary artery (n ¼ 1).
A total of 10 patients died within 30 days of surgery, for
an overall 30-day mortality of 13% (Table 3). The 30-dayThe Journal of Thoracic and Camortality decreased from 24% in the first cohort to 6%
in the second cohort (P ¼ .007). The 30-day mortality
decreased between the first and second cohorts in patients
with iPAH, CTD-PAH, and CHD-PAH (Table 2). Therdiovascular Surgery c Volume 143, Number 4 913
TABLE 3. Characteristics and outcomes of patients listed for lung transplantation
Variable Overall (n ¼ 100) iPAH (n ¼ 43) CHD (n ¼ 23) CTD (n ¼ 29) CTEPH (n ¼ 5) P value
Mean PA pressure (mm Hg) 50  14 47  9 67  14 48  14 44  13 <.0001
Cardiac output (L/min) 3.5  0.8 3.7  0.9 3.3  0.8 3.5  0.7 3.1  1.3 .2
NYHA class 3.3  0.5 3.2  0.5 3.3  0.7 3.3  0.5 3.3  0.5 .8
6-min Walk distance (m) 301  135 304  143 289  175 281  128 292  117 .9
In hospital to be bridged to Tx 17 (17) 11 (26) 3 (13) 3 (10) 0 .5
ECLS to be bridged to Tx 7 (7) 6 (14) 0 1 (3) 0 .1
Died on waiting list 18 (18) 5 (12) 2 (9) 10 (34) 1 (20) .01
Transplanted 79 (79) 38 (88) 21 (91) 16 (55) 4 (80)
Alive on waiting list 3 (3) 0 0 3 (11) 0
Bilateral lung Tx 57 (72) 34 (89) 4 (19) 15 (94) 4 (100) <.0001
Heart–lung Tx 22 (28) 4 (11) 17 (81) 1 (6) 0
Duration on waiting list (d) 197  252 81  71 378  306 163  298 263  152 <.0001
30-d Mortality 10 (13) 5 (13) 4 (19) 1 (6) 0 (0) .2
Severe primary graft dysfunction* 18 (23) 9 (24) 4 (19) 4 (25) 1 (25) .9
Length of ICU stay (d) 18  19 26  25 10  8 14  10 25  13 .01
Data presented as mean standard deviation or numbers, with percentages in parentheses. iPAH, Idiopathic arterial hypertension; CHD, congenital heart disease; CTD, connec-
tive tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; PA, pulmonary artery; NYHA, New York Heart Association; ECLS, extracorporeal life support;
Tx, transplantation; ICU, intensive care unit. *Defined by International Society for Heart and Lung Transplantation grade 3 during initial 72 hours after Tx.
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lung transplantation (P ¼ .2) and from 21% to 5% after
bilateral lung transplantation (P ¼ .06) between the first
and the second cohorts. The rate of severe PGD did not
change between the first and second cohorts (24% vs
16%, respectively; P ¼ .4).0 12 24 36 48 60 72 84 96 108 120
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FIGURE 2. Survival after lung transplantation. A, Overall survival; B, survival
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914 The Journal of Thoracic and Cardiovascular SurgIn the long term, the overall 5- and 10-year survival was
61% and 54%, respectively (Figure 2). The 5- and
10-year survival was similar after bilateral lung transplanta-
tion and heart–lung transplantation (Figure 2). The 10-year
survival, however, was worse for patients with iPAH than for
the other categories of patients with PAH (42% vs. 70%,t
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CTD-PAH achieved excellent long-term outcome with
a 10-year survival of 70% and 69%, respectively
(Figure 2). Of the 16 patients with CTD-PAH who under-
went transplantation, 13 had scleroderma. Although the
1-year survival improved from 72% to 81% between the
first and second cohorts, the long-term outcome was similar
between the 2 groups, with 5-year survival of 59% in the
first cohort and 62% in the second (Figure 2).
DISCUSSION
To the best of our knowledge, the present study is the first
to analyze the outcomes of all patients with PAH referred
for lung transplantation. Our results highlight that, in our
experience, 32% of the patients referred for lung transplan-
tation were listed for transplantation and 25% eventually
underwent transplantation. This reflects that a large number
of patients were suitable but too early to be listed because
we strongly encourage early referral to be able to rapidly
list these patients if their clinical status deteriorates faster
than expected. Despite this recommendation, however, we
observed that 11% of the patients still died before being
assessed in our program. The proportion of patients dying
before being assessed was similar in all PAH categories
and did not change over time, suggesting that this was likely
related to delayed referrals.
On average, the waiting list mortality was similar between
the present study and previous reports at 18%.1 However, the
waiting list mortality varied considerably according to the
underlying cause of PAH. The waiting list mortality reached
34% in patients with CTD-PAH and was 9% in patients with
CHD-PAH. In those with iPAH, the waiting list mortality
decreased from 25% in the first cohort to 0% in the second
cohort as a consequence of more aggressive management
while on the waiting list. Since 2006, we have used the
Novalung as a pumpless oxygenator connected between the
pulmonary artery and the left atrium to bridge patients with
PAH to lung transplantationwhenmedical therapy has failed,
including inotropic support.7 ECLS was mainly used for
patients with iPAH, because these are usually young patients
with limited co-morbidities. However, considering the high
waiting list mortality for patients with CTD-PAH, this group
should potentially also be given the option of ECLS in the
future. Although ECLS with either venoarterial extracorpo-
real membrane oxygenation or pulmonary artery to left
atrium Novalung can be associated with major morbidities,
an increasing number of centers have been using this option
to bridge patients with PAH to lung transplantation with good
results.5,9
The immediate postoperative recovery and long-term out-
comes of patients with CTD-PAHwere very good and poten-
tially even better than those for patients transplanted for
iPAH. The present series of 19 patients with CTD-PAH
undergoing bilateral lung transplantation is one of the largestThe Journal of Thoracic and Casingle-center experience reported. These results support
previous reports that have studied the outcomes of patients
with CTD undergoing lung transplantation and suggest that
the long-term outcomes of patients with CTD is similar to
that of other transplanted patients.10,11 These results should
therefore strongly encourage other programs to consider
patients with CTD for lung transplantation.
The degree of gastroesophageal reflux disease (GERD) is
always a potential concern in patients with CTD. In our
program, all patients undergo esophageal manometry study
and 24-hour impedance-pH monitoring of the esophagus at
their assessment for lung transplantation. We have observed
that the prevalence of GERD is high, regardless of the
underlying cause of end-stage lung disease and that the corre-
lation between preoperative GERD and the development of
bronchiolitis obliterans syndrome remains unclear.12 We
therefore do not disqualify patients from lung transplantation
by the severity of GERD alone. Postoperatively, lung trans-
plant recipients are treated according to their clinical symp-
toms, regardless of the findings on the preoperative workup
for GERD. A recent study from Savarino and colleagues13
suggested that GERD is more prominent in patients with
CTD presenting with severe interstitial lung disease. Hence,
considering that we have included only patients with
CTD-PAH and excluded those with a total lung capacity of
less than 60% in the present series, the degree of GERD
might have been less important than in those with CTD
without PAH and the long-term outcomes we observed after
lung transplantation in patients with CTD-PAH might not be
applicable to CTD patients without PAH.
The 30-day mortality after transplantation improved
from 24% in the first cohort to 6% in the second cohort.
In the second cohort, the 30-day mortality was 5% after
bilateral lung transplantation and 8% after heart–lung
transplantation. This improvement in early mortality after
lung transplantation correlates with previous reports show-
ing a significant improvement after lung transplantation in
the recent era and likely reflects better management of
PGD and right ventricular dysfunction.3 This observation
also correlates with the recent improvement in operative
mortality after pulmonary endarterectomy. The 30-day
mortality after elective pulmonary endarterectomy is cur-
rently less than 5% in our institution and other experienced
centers.14-16
Patients with CHD represent a unique group of patients.
Most of these patients require heart–lung transplantation
because of their congenital malformation and, thus, the
time on the waiting list was longer than for patients with
iPAH and CTD-PAH. However, those with CHD-PAH do
not decompensate as rapidly as those with CTD-PAH or
iPAH, and only 2 of the 23 patients with CHD-PAH who
we listed died on the waiting list. This finding correlates
with the very good long-term outcomes usually observed
for patients with CHD and highlights the difficulty inrdiovascular Surgery c Volume 143, Number 4 915
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heart–lung transplantation.17
The present series included 14 patients with CTEPH. Of
these 14 patients, 11 were not candidates for pulmonary
endarterectomy because distal disease and 3 had undergone
pulmonary endarterectomy at other institutions 6 to 14
years before their referral to our program for lung transplan-
tation. Since the start of our pulmonary endarterectomy
program in 2005, the indications for surgery have evolved.
We currently considered pulmonary endarterectomy for all
patients with evidence of chronic thromboembolic disease
localized in the segmental arteries or more proximally on
the pulmonary angiogram and/or CT pulmonary angiogram
regardless of the degree of right ventricular dysfunction or
the severity of the pulmonary vascular resistance. Thus,
very few patients with CTEPH have been referred for
lung transplantation in our institution since 2008.14
The present study had the limitations of a retrospective
data collection from a single center, including the analysis
of relatively small number of patients, inherent selection
bias, and the potential for missing data. We also included
all patients with CTD and mean pulmonary artery pressure
greater than 25 mmHg associated with a total lung capacity
greater than 60%. Although this definition has been used
by other groups studying patients with PAH diagnosed
with CTD, we did not re-review the CT scans to document
the degree of interstitial lung disease.18,19 Considering the
good results observed with this group of patients in the
present series, future prospective multicenter studies
should be performed to confirm our findings and analyze
patients with CTD in more detail.
In conclusion, our results have demonstrated that, in our
experience, 32% of patients with PAH referred for lung
transplantation are listed for transplantation and 25%
undergo transplantation. The 30-day mortality improved
over time for all categories of patients with PAH, although
the long-term outcomes remained unchanged. In contrast,
the waiting list mortality varied largely with the underlying
cause of PAH. The waiting list mortality was 34% in
patients with CTD-PAH but 0% for patients with iPAH
in the most recent cohort of patients. Patients with CTD-
PAH had excellent early and long-term outcomes after
lung transplantation and should potentially be more aggres-
sively treated on the waiting list, using ECLS if necessary.References
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Dr Kenneth R. McCurry (Cleveland, Ohio). Marc, that was
a very nice presentation and a very nice paper, and I would like
to congratulate you and the rest of your colleagues at the Univer-
sity of Toronto for the very nice manuscript you provided.
This is a rather large series of patients, at least by lung transplant
standards, and certainly for the orphan diagnosis of PAH for trans-
plantation from a very experienced center, the University of
Toronto. You demonstrate significantly improving 30-day out-
comes over a span of 14 years, and I would say excellent long-
term outcomes as well, so you are certainly to be congratulated
for that. I have 3 questions, Marc, regarding your approach and
how you achieved these very good outcomes. First, if I recall
correctly, you demonstrated a reduction in 30-day mortality fromery c April 2012
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X24% in your early era to 6% in the later era, with a fairly low mor-
tality of 5% in double-lung and 8% in heart–lung transplantations.
I think in your manuscript you attribute this to improved postoper-
ativemanagement. I wonder if you could enlighten us onwhat your
approach is and how you specifically have addressed these pa-
tients. As you know, a number of these patients have significant
right ventricular dysfunction issues and certainly can experience
difficulty perioperatively with primary graft dysfunction.
Dr de Perrot. Thank you, Ken.
Yes, I agree. I think we have improved our perioperative man-
agement of RV dysfunction over time, and I think that is certainly
what is translating into these results. For all patients with PAH, we
use cardiopulmonary bypass. Postoperatively, there are a number
of issues, I think, that have progressively changed over time.
One is that we don’t try to wake up these patients very early. We
keep them fully sedated for 2 or even 3 days after the surgery, until
the inflammatory condition from the bypass has had time to settle
down, the creatinine, if it rises, tends to normalize, and the lactate
normalizes. That allows us to keep the right ventricle a little bit
more under control. Thus, the lungs usually experience some de-
gree of dysfunction, but by keeping the patient asleep and being
able to manage their fluid status more precisely, you avoid that hy-
perdynamic flow through the lungs, and I think if you wait 2 or 3
days, you allow the lung to recover a little bit. Also, once the in-
flammatory condition settles down, you can start giving these
patients some Lasix and get them drier. They often come to the
OR with a large fluid overload and I think it’s important to start
getting that fluid out as soon as possible once the inflammatory
condition settles down. If you don’t do that, I think that fluid is pro-
gressively being redistributed from the tissue into the vascular
compartment and will aggravate the edema otherwise.
DrMcCurry.My second question relates really to the selection
of the operation. I think from the data you showed us, the vast
majority of congenital heart disease patients received heart–lung
transplantations, andmost iPAH and CTD patients received double
lungs, but there were a few heart–lung transplantations in that
patient population, and I think you specifically mentioned a low
left ventricular ejection fraction, but do you consider the right ven-
tricle and the degree of RV dysfunction in your decision-making?
Obviously you do, so I’m asking you where you draw the line and
when do you think you need to go to a heart–lung in iPAH patients
or CTD patients.
Dr de Perrot. It’s always a very difficult decision and a point of
a lot of discussion among our group as well. Clearly, if the left ven-
tricle is dysfunctional, there is no doubt. Most of the patients who
hadheart-lung transplantation for iPAHorCTDhadLVdysfunction.
For RV dysfunction, we usually still do a bilateral lung transplant.
Even if the RV is significantly dysfunctional, wewill still do a bilat-
eral lung transplant. I don’t think we have ever done a heart-lung be-
cause the RV was too dysfunctional. But it has always led to some
discussion in our group. At this point, I don’t think we have enough
evidence as to when the RV is too far gone and when the RV is fi-
brotic. The RV has a good capability to recover after the surgery,
but itmight not fully recover, and certainly it contributes to somedif-
ficulty perioperatively. Someof the difficulty is to see how strong the
RV is, and I don’t think the cardiac index or other hemodynamic pa-
rameters allow you to make a decision as to the strength of the RV.
The B-type natriuretic peptide (BNP) or maybe the magneticThe Journal of Thoracic and Caresonance imaging in the future will allow us to have a better idea
of the myocardium in the RV, but at this point I don’t think we
have enough data to really tease out the function of theRV. The other
parameter is the LV dysfunction. If the LV is dysfunctional on the
echocardiographic, then there is no doubt. But what you can see as
well is that the LV can beworking preoperatively just because there
is no flow going to the LV, and once you unload the pulmonary vas-
culature, the cardiac output to the LV increases and the LV becomes
dysfunctional postoperatively. That has been well described. Partic-
ularly in Vienna,Walter Klepetko described that a few years ago. So
theLVgets somedegree of atrophy because of the pulmonary hyper-
tension, and it’s also something that’s difficult to tease out preoper-
atively because it’s part of the same problem, I think.
Dr McCurry. You have a difficult dilemma sometimes and no
clear answer.
I have one final question about your bridging strategies. The
data you demonstrated, Marc, showed us an increasing willingness
to bridge patients with PAH to lung transplantation. I think 7%
of your population was bridged, and all in the past 5 years. Obvi-
ously, you and other groups in Europe have led with the use of the
Novalung, and there are a lot of strategies to try to bridge these
patients—VV-ECMO, VA-ECMO, balloon septostomy with
VV-ECMO, Novalung. Can you give us a bit of insight into what
your program thoughts are right now?
Dr de Perrot. Yes. What we mostly use in these patients, or
what we use when we can, is the Novalung connected between
the pulmonary artery and the left atrium. We use the oxygenator,
the Novalung, the membrane without any pump. The RV creates
the pump to generate the flow through the Novalung, and that al-
lows unloading of the RVand creates a right-to-left shunt with ox-
ygenation of the blood, which really allows the patient to stabilize
immediately once it’s connected. Also, because of the central can-
nulation, it allows the patients to be mobilized.
Once they are extubated and have awakened from the surgery,
they can be mobilized until their transplant. We even currently
have 1 patient who has been on the PA–LA Novalung for 3 months
and is still waiting. So you can really bridge these patients for
a number of weeks at least, if not months, by that mechanism. It
requires a sternotomy and you can have some difficulty with bleed-
ing, which eventually needs to be controlled, but once things settle
down, it’s a very nice way to bridge them. The alternative is the
VA-ECMO, or the group at the University of Maryland has de-
scribed the VV-ECMO with an interatrial shunt to generate the
flow through the left cavity of the heart. But certainly I would
never recommend doing any LVAD for these patients. By putting
an LVAD without any oxygenator, you’re facing a major problem
with potential hypoxemia, as well as bleeding from the cannulas
due to the high PA pressure, and you really have to bypass the
lungs with whatever technique you use.
Dr McCurry. Thank you, Marc. It was a nice paper and excel-
lent outcomes.
Dr Andrew C. Chang (Ann Arbor, Mich).Dr. de Perrot, I thank
you and your colleagues for presenting your experience at Toronto.
You had pointed out that about 22%, one fifth of the patients in
your cohort, were thought initially to be too well for transplanta-
tion. Could you comment on your selection criteria? As you
have noted this is a difficult population to decide on listing for
transplantation, and I would appreciate your insights in that regard.rdiovascular Surgery c Volume 143, Number 4 917
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XDr de Perrot. Our recommendation is to really assess these
patients early on. At least with the pulmonary hypertension
program at Toronto General, when patients go on Flolan, that is
typically when we assess these patients, and then we watch them
on Flolan, and if they deteriorate on Flolan, and sometimes they
can deteriorate relatively quickly, wewill be able to list them emer-
gently and have them ready within a few days, and if they do well,
then we have the assessment data that we can maintain for several
years, and if they come to transplant later, then you repeat a few of
the investigations, but at least they know what transplant means,
we know they are eligible, and we can list them relatively quickly
that way. That’s what our recommendation has been. But despite
that, what our analysis shows is that you still have 10% to 15%
of the patients who die even before reaching an assessment. There
are fewer patients dying now between the assessment and the list-
ing. That’s something that has decreased progressively. But there
are still 10%, 15% of the patients who are referred way too late
and they don’t even make it to an assessment because of the late
referral, and that’s really something that we try to avoid by having
an early referral. But it’s always a very difficult decision as towhen
to list them, when is the right time.918 The Journal of Thoracic and Cardiovascular SurgDr Chang. Do you think there’s any utility in using a biochem-
ical marker? Could you elaborate on your use of serum BNP
measurement, for example?
Dr de Perrot. Yes. We are using BNP more and more. BNP has
been very useful to tease out some of the responses to the PH ther-
apy and to seewhether it translates into better outcome if your BNP
decreases on any of the PH medications. So we use it as a marker.
We don’t really use it once they are on thewaiting list. If the BNP is
high or the BNP goes up, that certainly can be a sign that suggests
that you should potentially list these patients. We should probably
use the BNPmore often.We have done only a few cases. But one of
the difficult decisions is alsowhen you should bridge these patients
with the Novalung, extracorporeal life support. Initially, we were
really pushing the limit by doing that too late, and 1 patient even
arrested on theway to the operating room. I think as we have gotten
more confident with ECLS, we have been bridging these patients
earlier on, and I think BNP is also one parameter you can follow
once you have to put the patients on inotropes. If their BNP doesn’t
come down or stays very high, this potentially would be an indica-
tion to go on ECLS to do it in a better condition than urgently in the
middle of the night.ery c April 2012
